A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide
Purpose: The survival times of glioblastoma (GB) patients after the standard therapy including safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide are heterogeneous. In order to define a simple, reliable method for predicting whether patients with isocitrate de...
Guardado en:
Autores principales: | Anne Clavreul, Jean-Michel Lemée, Gwénaëlle Soulard, Audrey Rousseau, Philippe Menei |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f0c23537c00436eb01fbe8635bfe195 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Fabiana Gregucci, et al.
Publicado: (2021) -
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
por: Clavreul A, et al.
Publicado: (2019) -
Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response
por: Justin Bo-Kai Hsu, et al.
Publicado: (2021) -
Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis
por: Tim Wende, et al.
Publicado: (2021) -
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide
por: Yiming Ding, et al.
Publicado: (2021)